The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
about
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesityThe endocannabinoid system as an emerging target of pharmacotherapyActivation of the peripheral endocannabinoid system in human obesityPSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in ratsPrevalence, predisposition and prevention of type II diabetes.Obesity pharmacotherapy: current perspectives and future directionsMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationPlasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic miceCB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivityObesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorshipVagus nerve stimulation reduces body weight and fat mass in ratsEffects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat dietCB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptorsCannabinoids, eating behaviour, and energy homeostasis.The endocannabinoid system: a new pharmacological target for obesity treatment?Stress regulates endocannabinoid-CB1 receptor signaling.Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available dataCB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.Dysregulation of the endocannabinoid system in obesity.Identification of endocannabinoids and related compounds in human fat cells.Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cellsCB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese miceFood for thought: endocannabinoid modulation of lipogenesis.The endocannabinoid system: potential for reducing cardiometabolic riskPeripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats.CNR1 genotype influences HDL-cholesterol response to change in dietary fat intakePeripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.New insights on the role of the endocannabinoid system in the regulation of energy balance.The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.Psychiatric adverse effects of rimonobant in adults with Prader Willi syndromeThe endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II.
P2860
Q24523292-BE175C00-65B6-433B-9322-62D21DAE1FE5Q24648473-9B9180C0-87A1-4B8E-80B7-F41878862F24Q24655297-AF72AC7D-9F62-4D67-B34A-AFFD1A914192Q24681458-10EEEA74-9892-46D1-A70A-C5E373747304Q24815863-AB452641-7B46-4F15-AB55-0C514CA863ECQ26828559-18E7CDF0-110E-4C8C-BB60-32C861EC0DF8Q26829111-C79C5D50-C64F-4112-9635-1580B5D3F0DAQ27344569-BE3F0653-F929-494C-9BDC-104080E88403Q28242954-AFE24E7D-8A83-4C26-99C3-9B92265F0437Q28475155-16270C01-B49D-47F7-BA0C-F8481ECBFB58Q28484122-C6315AD4-D551-45B2-84FF-687C6E3B2ACBQ28576328-E30DBE11-E9B7-4112-BD78-8F1031F0BC00Q28610813-CC701110-B10A-4526-940A-6D23098B7BA2Q30357350-76589E53-D045-4ED7-8E6A-D6F1CDAEDA4AQ30377157-F37DC5DC-EEF5-4A1D-837A-F57A655D957AQ30402136-AD1D1D37-708E-483B-9C27-950958BC5CABQ31059589-B5A6E10A-BD5D-4905-9AC1-E4D3995E6B18Q31116375-0B4FFF41-C4A6-4CEC-8366-5B4AA9BA70C5Q33289034-B66F19B7-D088-425E-848B-62698B47D96BQ33345484-2527F049-08C7-4598-BC0E-648039A4F8F1Q33437059-677CA0AB-955F-4094-9845-56161AD40532Q33604478-CF9C5D40-32C8-4AC1-8214-746A04119750Q33750744-A771352C-F169-442A-9239-734379619EC9Q33768340-D8C0D805-9E6F-41A5-BEBA-C536E09EA072Q33999727-772B32CA-32A6-4CF2-88BA-D07C299019DAQ34028741-15C93A56-AB69-4D62-B800-4FC0548C3AC8Q34098873-904C292D-3566-420C-B711-AE95648C6F45Q34222264-A5A510CA-0D91-4B39-8C1B-E71C4F70334DQ34261731-01CDFFDA-B867-4702-A29E-A8DF2C8E3D31Q34290823-63C692B8-94FD-40B6-AAF5-B1F1263886B3Q34369293-095477C9-1AD4-456A-B05E-2BD177172A38Q34494301-65F92890-64D8-47FB-A187-32CB44316358Q34504906-3463DAD8-3947-4C38-8B28-9D9DAFF06ED0Q34570954-B0E65E36-E1B5-4D89-98A8-07FBB4C32AADQ34587990-7BFD87F4-1FDA-4125-93B5-52BDBB2B17ACQ34626755-3F8C93FA-9360-4D8A-93F6-6E8221E73507Q34866320-9484B1FA-F880-4587-83C2-41C77AA0E1BAQ34992139-B67DC05C-6301-4DAC-B76D-C0CB18F035D2Q35006445-D38D000D-CFB5-4403-9DF1-D0C6CFD5FBBCQ35048879-0C9D78F1-BE7F-4624-BEDB-D549971CDB14
P2860
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
description
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im April 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/04/01)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/04/01)
@nl
наукова стаття, опублікована у квітні 2003
@uk
مقالة علمية (نشرت في أبريل 2003)
@ar
name
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@ast
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@en
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@nl
type
label
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@ast
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@en
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@nl
prefLabel
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@ast
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@en
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@nl
P2093
P921
P3181
P356
P1476
The cannabinoid CB1 receptor a ...... nd in cultured adipocyte cells
@en
P2093
A. Esclangon
F. Oury-Donat
J. P. Maffrand
M. Bensaid
M. Gary-Bobo
P. Soubrié
P304
P3181
P356
10.1124/MOL.63.4.908
P577
2003-04-01T00:00:00Z